NASDAQ: NKTR - Nektar Therapeutics

Rentabilidade por seis meses: -45.04%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Nektar Therapeutics

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Nektar Therapeutics

Nektar Therapeutics, биофармацевтическая компания, исследует и разрабатывает лекарства-кандидаты от рака и аутоиммунных заболеваний в США.

mais detalhes
Компания разрабатывает бемпегалдеслейкин, агонист пути CD122-предпочтительного интерлейкина-2 (IL-2), который находится в стадии 3 клинических испытаний для лечения метастатической меланомы, почечно-клеточной карциномы, инвазивного рака мочевого пузыря и адъювантной меланомы; фаза 2 клинических испытаний по лечению почечно-клеточного рака и уротелиального рака; фаза 1 / 2A клинических испытаний по лечению плоскоклеточного рака головы и шеи; фаза 1/2 клинических испытаний по лечению немелкоклеточного рака легких и иммуноонкологии; и фазы 1B клинических испытаний для лечения COVID-19. Также разрабатывается NKTR-358, цитокиновый стимулятор Treg, который находится в фазе 2 клинических испытаний для лечения системной красной волчанки и язвенного колита, а также клинические испытания фазы 1B для лечения атопический дерматит и псориаз; NKTR-255, агонист рецептора IL-15, который находится в фазе 2 клинических испытаний для лечения неходжкинской лимфомы и множественной миеломы, а также рака головы и шеи и рака прямой кишки; и NKTR-262, агонист толл-подобных рецепторов, который находится в фазе 1/2 клинических испытаний для лечения местнораспространенных или метастатических злокачественных опухолей солидных опухолей, а также различных других лекарственных препаратов-кандидатов. Компания имеет соглашения о сотрудничестве с Takeda Pharmaceutical Company Ltd .; AstraZeneca AB; UCB Pharma S.A .; Ф. Хоффманн-Ла Рош Лтд; Bausch Health Companies Inc .; Pfizer Inc .; Amgen Inc .; UCB Pharma (Биоген); Bristol-Myers Squibb Company; Baxalta Incorporated; «Эли Лилли и компания»; и SFJ Pharmaceuticals, Inc. Nektar Therapeutics была зарегистрирована в 1990 году, ее штаб-квартира находится в Сан-Франциско, Калифорния.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 1994-05-03
ISIN US6402681083
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 0
Сайт http://www.nektar.com
Цена ао 0.731
Alteração de preço por dia: 0% (0.731)
Alteração de preço por semana: +4.28% (0.701)
Alteração de preço por mês: -18.78% (0.9)
Alteração de preço em 3 meses: -37.52% (1.17)
Mudança de preço em seis meses: -45.04% (1.33)
Mudança de preço por ano: -1.22% (0.74)
Mudança de preço em 3 anos: -83.68% (4.48)
Mudança de preço em 5 anos: -95.64% (16.76)
Mudança de preço em 10 anos: -95.39% (15.87)
Mudança de preço desde o início do ano: -19.48% (0.9078)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 1.08 9
P/BV 0.7398 10
P/E 0 0
EV/EBITDA -2.37 0
Total: 6.13

Eficiência

Nome Significado Nota
ROA, % -69.36 0
ROE, % -210.75 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -1.78 10
Total: 9.8

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -21.36 0
Rentabilidade Ebitda, % -36.11 0
Rentabilidade EPS, % -42.34 0
Total: 0
Mais detalhes

Data da transação Data de divulgação Insider Tipo Preço Volume Quantidade Compartilhe até, % Compartilhe depois, % Documento
19.02.2025 19.02.2025 Zalevsky Jonathan
Officer		 Comprar 1.01 10 403 10300 0 0.01 link
19.02.2025 19.02.2025 ROBIN HOWARD W
Officer		 Comprar 1.01 24 012 23774 0 0.01 link
19.02.2025 19.02.2025 Wilson Mark Andrew
Officer		 Comprar 1.01 11 150 11040 0 0.01 link
24.12.2024 26.12.2024 Wilson Mark Andrew
Chief Legal Officer		 Oferta 0.89 14 738 16560 0 -0.01 link
23.12.2024 26.12.2024 Wilson Mark Andrew
Chief Legal Officer		 Oferta 0.9 30 062 33402 0 -0.02 link
23.12.2024 23.12.2024 Wilson Mark Andrew
Officer		 Comprar 0.9 30 062 33402 0 0.02 link
19.12.2024 20.12.2024 Zalevsky Jonathan
Chief R&D Officer		 Oferta 0.94 48 048 51115 0 -0.03 link
19.12.2024 19.12.2024 Zalevsky Jonathan
Officer		 Comprar 0.94 48 048 51115 0 0.03 link
18.12.2024 19.12.2024 ROBIN HOWARD W
President & CEO		 Oferta 0.99 84 185 85035 0 -0.05 link
17.12.2024 19.12.2024 ROBIN HOWARD W
President & CEO		 Oferta 1.01 47 465 46995 0 -0.03 link
17.12.2024 17.12.2024 ROBIN HOWARD W
Officer		 Comprar 1.01 47 465 46995 0 0.03 link
19.11.2024 20.11.2024 ROBIN HOWARD W
President & CEO		 Oferta 1.01 16 441 16278 0 -0.01 link
19.11.2024 20.11.2024 Wilson Mark Andrew
Chief Legal Officer		 Oferta 1.01 6 471 6407 0 0 link
19.11.2024 20.11.2024 Zalevsky Jonathan
Chief R&D Officer		 Oferta 1.01 7 863 7785 0 0 link
19.11.2024 19.11.2024 ROBIN HOWARD W
Officer		 Comprar 1.01 16 441 16278 0 0.01 link
19.11.2024 19.11.2024 Wilson Mark Andrew
Officer		 Comprar 1.01 6 471 6407 0 0 link
19.08.2024 20.08.2024 ROBIN HOWARD W
President & CEO		 Oferta 1.28 19 048 14881 0 -0.01 link
19.08.2024 20.08.2024 Wilson Mark Andrew
Chief Legal Officer		 Oferta 1.28 7 233 5651 0 0 link
19.08.2024 20.08.2024 Zalevsky Jonathan
Chief R&D Officer		 Oferta 1.28 8 788 6866 0 0 link
17.05.2024 20.05.2024 Wilson Mark Andrew
Chief Legal Officer		 Oferta 1.75 10 955 6260 0 0 link
17.05.2024 20.05.2024 Zalevsky Jonathan
Chief R&D Officer		 Oferta 1.75 12 871 7355 0 0 link
17.05.2024 20.05.2024 ROBIN HOWARD W
President & CEO		 Oferta 1.75 29 138 16650 0 -0.01 link
20.02.2024 22.02.2024 ROBIN HOWARD W
President & CEO		 Oferta 0.68 13 622 20033 0 -0.01 link
20.02.2024 22.02.2024 Wilson Mark Andrew
Chief Legal Officer		 Oferta 0.68 5 172 7606 0 0 link
20.02.2024 22.02.2024 Zalevsky Jonathan
Chief R&D Officer		 Oferta 0.68 6 130 9014 0 0 link
18.09.2023 20.09.2023 Ajer Jeffrey Robert
Director		 Oferta 0.69 3 008 4359 0 0 link
18.09.2023 20.09.2023 Curet Myriam
Director		 Oferta 0.69 3 008 4359 0 0 link
16.02.2023 17.02.2023 ROBIN HOWARD W
President & CEO		 Oferta 3 58 905 19635 0 -0.01 link
16.02.2023 17.02.2023 Thomsen Jillian B.
Chief Financial Officer		 Oferta 3 30 801 10267 0 -0.01 link
16.02.2023 17.02.2023 Wilson Mark Andrew
Chief Legal Officer		 Oferta 3 24 825 8275 0 0 link
16.02.2023 17.02.2023 Zalevsky Jonathan
Chief R&D Officer		 Oferta 3 31 452 10484 0 -0.01 link
16.11.2022 18.11.2022 ROBIN HOWARD W
President & CEO		 Oferta 3.57 135 710 38014 0 -0.02 link
16.11.2022 18.11.2022 Thomsen Jillian B.
Chief Financial Officer		 Oferta 3.57 39 609 11095 0 -0.01 link
16.11.2022 18.11.2022 Wilson Mark Andrew
Chief Legal Officer		 Oferta 3.57 31 023 8690 0 0 link
16.11.2022 18.11.2022 Zalevsky Jonathan
Chief R&D Officer		 Oferta 3.57 48 052 13460 0 -0.01 link
23.09.2022 26.09.2022 Ajer Jeffrey Robert
Director		 Oferta 3.16 13 266 4198 0 0 link
23.09.2022 26.09.2022 Curet Myriam
Director		 Oferta 3.16 13 266 4198 0 0 link
22.09.2022 20.09.2023 CHESS ROBERT
Director		 Oferta 0.67 6 834 10200 0 -0.01 link
22.09.2022 26.09.2022 CHESS ROBERT
Director		 Oferta 3.19 16 269 5100 0 0 link
16.02.2022 18.02.2022 Labrucherie Gil M
SVP, COO & CFO		 Oferta 10.95 82 990 7579 0 0 link
16.02.2022 18.02.2022 NORTHCOTT JOHN
SVP & Chief Commercial Officer		 Oferta 10.95 53 129 4852 0 0 link
16.02.2022 18.02.2022 ROBIN HOWARD W
President & CEO		 Oferta 10.95 136 656 12480 0 -0.01 link
16.02.2022 18.02.2022 Thomsen Jillian B.
SVP & Chief Accounting Officer		 Oferta 10.95 25 875 2363 0 0 link
16.02.2022 18.02.2022 Wilson Mark Andrew
SVP & General Counsel		 Oferta 10.95 40 088 3661 0 0 link
16.02.2022 18.02.2022 Zalevsky Jonathan
Chief R&D Officer		 Oferta 10.95 119 486 10912 0 -0.01 link
18.11.2021 18.11.2021 Labrucherie Gil M
SVP, COO & CFO		 Oferta 12.69 38 070 3000 0 0 link
16.11.2021 18.11.2021 Labrucherie Gil M
SVP, COO & CFO		 Oferta 13.16 278 321 21149 0 -0.01 link
16.08.2021 18.08.2021 Thomsen Jillian B.
SVP & Chief Accounting Officer		 Oferta 13.83 184 478 13339 0 -0.01 link
16.08.2021 18.08.2021 ROBIN HOWARD W
President & CEO		 Oferta 13.83 159 252 11515 0 -0.01 link
16.08.2021 18.08.2021 Wilson Mark Andrew
SVP & General Counsel		 Oferta 13.83 26 415 1910 0 0 link
16.08.2021 18.08.2021 Zalevsky Jonathan
Chief R&D Officer		 Oferta 13.83 105 965 7662 0 0 link
22.07.2021 22.07.2021 CHESS ROBERT
Director		 Oferta 16.8 1 529 91 0 0 link
22.07.2021 22.07.2021 CHESS ROBERT
Director		 Comprar 13.8 1 256 91 0 0 link
21.07.2021 22.07.2021 CHESS ROBERT
Director		 Oferta 16.81 59 238 3524 0 0 link
21.07.2021 22.07.2021 CHESS ROBERT
Director		 Comprar 13.8 48 631 3524 0 0 link
20.07.2021 22.07.2021 CHESS ROBERT
Director		 Oferta 16.8 35 381 2106 0 0 link
20.07.2021 22.07.2021 CHESS ROBERT
Director		 Comprar 13.8 29 063 2106 0 0 link
17.05.2021 19.05.2021 Labrucherie Gil M
SVP, COO & CFO		 Oferta 18.3 144 533 7898 0 0 link
17.05.2021 19.05.2021 NORTHCOTT JOHN
SVP & Chief Commercial Officer		 Oferta 18.3 111 356 6085 0 0 link
17.05.2021 19.05.2021 ROBIN HOWARD W
President & CEO		 Oferta 18.3 211 548 11560 0 -0.01 link
17.05.2021 19.05.2021 Thomsen Jillian B.
SVP & Chief Accounting Officer		 Oferta 18.3 245 055 13391 0 -0.01 link
17.05.2021 19.05.2021 Wilson Mark Andrew
SVP & General Counsel		 Oferta 18.3 35 081 1917 0 0 link
28.01.2021 29.01.2021 Thomsen Jillian B.
SVP & Chief Accounting Officer		 Oferta 18.62 1 396 500 75000 0 -0.04 link
28.01.2021 29.01.2021 Thomsen Jillian B.
SVP & Chief Accounting Officer		 Comprar 8.8 660 000 75000 0 0.04 link
15.12.2020 17.12.2020 Myriam Curet
Director		 Oferta 17.82 27 799 1560 0 0 link

Instituições Volume Compartilhar, %
Deep Track Capital, LP 18400000 10.02
Vanguard Group Inc 12042873 6.56
Acadian Asset Management. LLC 7818804 4.26
PRIMECAP Management Company 7001747 3.81
Blackrock Inc. 6104217 3.32
Monaco Asset Management SAM 5973387 3.25
Citadel Advisors Llc 5625000 3.06
Renaissance Technologies, LLC 5325475 2.9
GSA Capital Partners LLP 5255790 2.86
Shaw D.E. & Co., Inc. 4098844 2.23

ETF Compartilhar, % Rentabilidade para o ano, % Dividendos, %
ProShares UltraShort Nasdaq Biotechnology 0.48 -40.36 1.76
iShares Micro-Cap ETF 0.05855 17.09 1.54048
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.02711 31.36 1.41955
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.02626 17.58 1.75869
Vanguard Russell 2000 ETF 0.01 17.16 1.48801
Schwab U.S. Small-Cap ETF 0.00608 17.47 1.51433
ProShares UltraPro Russell2000 0.00502 89.82 1.47873
ProShares Hedge Replication ETF 0.00137 5.92 1.47892
Schwab U.S. Broad Market ETF 0.00051 24.86 1.43354
Vanguard Russell 3000 ETF 0 31.87 1.43817



Supervisor Cargo Pagamento Ano de nascimento
Mr. Howard W. Robin CEO, President & Director 1.83M 1953 (72 ano)
Mr. Mark A. Wilson Senior VP, Chief Legal Officer & Secretary 749.99k 1972 (53 ano)
Ms. Jennifer Ruddock Chief Business Officer N/A
Mr. Robert Bacci Senior Vice President of Human Resources & Facilities Operations N/A
Dr. Mary Tagliaferri L.Ac., M.D. Chief Medical Officer N/A 1966 (59 anos)
Dr. Jonathan Zalevsky Ph.D. Chief Research & Development Officer 1.25M 1975 (50 anos)
Vivian Wu Director of Investor Relations & Corporate Affairs N/A
Ms. Sandra A. Gardiner Chief Financial Officer N/A 1966 (59 anos)

Endereço: United States, San Francisco, CA , 455 Mission Bay Boulevard South - abrir no Google Maps, abrir mapas Yandex
Site: http://www.nektar.com